Mark G. Currie - Jun 7, 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Director
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Jun 7, 2022
Transactions value $
-$68,538
Form type
4
Date filed
6/9/2022, 05:04 PM
Previous filing
Jun 3, 2022
Next filing
Aug 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Options Exercise $2.22M +190K +32.17% $11.65 782K Jun 7, 2022 Direct
transaction IRWD Class A Common Stock Sale -$2.29M -190K -24.34% $12.01 592K Jun 7, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRWD Employee Stock Option (Right to Buy) Options Exercise $0 -190K -100% $0.00* 0 Jun 7, 2022 Class A Common Stock 190K $11.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The option, vested as to 1.25% on each monthly anniversary of the vesting commencement date for the first 36 months, and as to 4.5833% of the award on each monthly anniversary thereafter, is presently exercisable in full.